Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Extra copies of chromosome 1q21 (+ 1q: gain= 3 copies, amp>= 4 copies) are associated
with worse outcomes in multiple myeloma (MM). This systematic review assesses the current …

Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple
myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to …

Importance Cancer treatment can result in burdensome toxic effects that profoundly affect
patient quality of life. In seeking to emphasize the efficacy of tested treatments, clinical trial …

Use of surrogate end‐points such as progression‐free survival (PFS) and other time‐to‐
event (TTE) end‐points is common in multiple myeloma (MM) clinical trials. This systematic …

The ethical permissibility of randomized controlled trials (RCTs) depends on clinical
equipoise at the time of trial enrollment—the existence of uncertainty about which treatment …

Background As the landscape of haematological malignancies dramatically changes due to
diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial …

Median overall survival for patients with newly diagnosed multiple myeloma may surpass
ten years. Nonetheless, many patients face considerable treatment-related morbidity and …

Aim: The correlation between response and survival has not been well-studied in relapsed
or refractory multiple myeloma (RRMM). Materials & methods: A systematic literature review …

Purpose Many clinical trials of therapeutic interventions for multiple myeloma do not use
patient important outcomes and rely on the use of surrogate endpoints. The aim of this …